Sun Pharmaceutical Industries Limited

Overview

Sun Pharmaceutical Industries Limited isn't any. 4th Global and no. 1 Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients primarily in India and the US.

Over 72% of Sun Pharma sales are from markets outside India, primarily within us. The U.S. is the single largest market, accounting for about 50% of its turnover; altogether, formulations or finished dosage forms account for 93% of the turnover. Moreover, manufacturing is across 26 locations, including plants within the US, Canada, Brazil, Mexico, and Israel. Only in the U.S., the corporate markets an outsized basket of generics, with a robust pipeline awaiting approval from the U.S. Food and Drug Administration (FDA).

Sun Pharma was listed on the stock market in 1994 in a problem oversubscribed 55 times. The founding family continues to carry a majority stake within the company. Today Sun Pharma is the second-largest and, therefore the most profitable drug company in India. The most significant drug company by market capitalization on the Indian exchanges.

The Indian pharmaceutical industry has become the third-largest producer within the world in terms of volumes and is poised to grow into an industry of $36.7 billion from $20 billion in 2015. In terms of usefulness, India still stands at number 14 within the world.

In 2009 Sun Pharma's Caraco Pharmaceutical's plant in Detroit was closed thanks to unsanitary conditions leading to the seizure of $20 million of medicine by the FDA for contamination issues

Showing all 7 results

Show sidebar